BIO 2015

Wuxi and University of Pennsylvania partner on vector production

By Fiona BARRY

- Last updated on GMT

Wuxi and University of Pennsylvania announced their collaboration at BIO 2015 in Philadelphia this week.
Wuxi and University of Pennsylvania announced their collaboration at BIO 2015 in Philadelphia this week.
Contract research organisation WuXi has entered a manufacturing collaboration with the University of Pennsylvania to produce gene therapy vectors.

The deal will see Penn scientists work with Wuxi Apptec  on scalable GMP production at Wuxi’s 145,000 sq ft facility at the Navy Yard in Philadelphia, currently under construction.

Advances in the technology of gene transfer developed at the University of Pennsylvania have ushered in an era of exciting translational research in gene therapy​” said the director of the Gene Therapy Program and the Orphan Disease Center within the Perelman School of Medicine at Penn.

James Wilson continued, “A critical step toward successful commercialization of these products is the development of processes and analytics for scalable production of vectors.​”

AAV and lentiviruses

Pennsylvania’s Gene Therapy Program focuses on developing gene vectors derived from recombinant viruses, especially novel adenoassociated virus (AAV) vectors, although some of the work involves adenoviruses and lentiviruses. The research is aimed at orphan and infectious diseases.

 “We are delighted to partner with the University of Pennsylvania to provide an integrated solution for cGMP viral vector manufacturing to advance the many exciting clinical programs underway,” ​said Felix Hsu, Senior Vice President of Wuxi’s US Operations.

The ability to deploy advanced analytical tools, an ongoing technical collaboration, and application of the knowhow developed at Penn and in Dr Jim Wilson’s laboratory will be particularly valuable as we expand our clinical and commercial manufacturing of AAV vectors here in Philadelphia.

The partnership is the result of work by the Penn Center for Innovation (PCI), the University’s commercialization organization, which is builds strategic partnerships with the private sector.

Related news

Show more

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars